Letter to the Editor
Sir: Hyperprolactinemia is a well-recognized complication
of some antipsychotic agents that results from the blocking of
dopamine-2 (D2) receptors in the anterior pituitary. Aripiprazole,
a potent partial agonist of the D2 receptors, inhibits spontaneous
prolactin release from isolated anterior pituitary slices. Clinically,
switching to aripiprazole monotherapy resolves antipsychoticinduced
hyperprolactinemia.
From the Editors
Are you a healthcare provider?
Add your NPI to personalize your JCP experience.
This PDF is free for all visitors!